# OnCo record nct05224141 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05224141/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05224141", "NCT05224141" ;
  schema:name "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)"@en ;
  schema:alternateName "KEYVIBE-008"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Etoposide, Cisplatin, Atezolizumab and Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05224141/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05224141> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-03-24" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> .